Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This study found that a combination of the Tri-energy factor 5.5% booster and photodynamic therapy significantly improved hair density and reduced single follicular units in patients with androgenetic alopecia, compared to minoxidil or booster alone, supporting the inclusion of photodynamic therapy in comprehensive treatment.

This integrative review found that triamcinolone hexacetonide remains the primary treatment for mild to moderate alopecia areata but noted its significant side effects with prolonged use, while emerging therapies like PRP and minoxidil offer promising alternative benefits with fewer risks.

Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.

This study evaluated Tridax procumbens extracts for their in-vitro alpha amylase inhibitory activity compared to standard antidiabetic agents, suggesting potential benefits for diabetes management.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.

This study found that the penta-peptide Gly-Pro-Ile-Gly-Ser increased the proportion of thick hair and improved baldness appearance in Japanese men with androgenetic alopecia.

In this study, 5-aminolevulinic acid photodynamic therapy did not improve hair growth in patients with androgenetic alopecia but was safe and slightly reduced scalp sebum secretion.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

The document's conclusion cannot be determined from the provided text.

This study found that adding fexofenadine to DPCP treatment in non-atopic Alopecia areata patients did not significantly improve hair regrowth, but it did significantly reduce treatment-related discomfort.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that a 5-mer peptide called P5 promotes hair growth by activating adiponectin receptor 1, suggesting its potential use as a topical treatment for alopecia.

In this study, ALP knockdown significantly impaired the hair follicle-inducing capacity of human dermal papilla spheres, highlighting a critical role for ALP in hair follicle neogenesis.